Background
Methods
Data source
Study population
Adverse events of interest
AE category | Physician-reported AEs included in the analysis |
---|---|
SIEs | Infections for which the patient was hospitalized and/or received intravenous antibiotics, which were categorized as follows: joint/bursa, cellulitis/skin, sinusitis, diverticulitis, sepsis, pneumonia, bronchitis, gastroenteritis, meningitis/encephalitis, urinary tract infection, upper respiratory infection, active tuberculosis (latent tuberculosis infection was not included), and other infections |
SIE microorganism | Opportunistic infections: coccidioidomycosis, Cryptococcus, herpes zoster, histoplasmosis, John Cunningham virus, Listeria, Pneumocystis, active tuberculosis (latent tuberculosis infection was not included), and other opportunistic infections. Nonopportunistic infections: methicillin-resistant Staphylococcus aureus (MRSA), bacterial infection other than MRSA, and other nonopportunistic infections |
Malignancies | Nonmelanoma skin cancer, melanoma skin cancer, lymphoma, breast cancer, lung cancer, and other cancers |
CVEs | Myocardial infarction, transient ischemic attack, stroke, congestive heart failure with hospitalization, cardiac revascularization procedure, ventricular arrhythmia, cardiac arrest, acute coronary syndrome, unstable angina, hypertension with hospitalization, peripheral arterial thromboembolic event, urgent peripheral arterial revascularization, peripheral ischemia or gangrene (necrosis), and other CVEs |
Propensity score matching
Statistical analysis
Results
Baseline demographics
Before PS matching | After PS matching | |||||
---|---|---|---|---|---|---|
CZP (n = 975) | Other TNFi (n = 5240) | Nominal p value | CZP (n = 952) | Other TNFi (n = 952) | Nominal p value | |
Demographics | ||||||
Age, years, median (IQR) | 58 (18.0) | 56 (16.5) | < 0.001 | 58 (17.0) | 58 (16.0) | 0.48 |
Female sex, n (%) | 769 (78.9) | 4107 (78.4) | 0.74 | 751 (78.9) | 750 (78.8) | 0.96 |
Race, white, n (%) | 840 (86.2) | 4310 (82.3) | < 0.001 | 820 (86.1) | 786 (82.6) | 0.03a
|
BMI, kg/m2, mean (SD) | 30.0 (7.3) | 30.1 (7.3) | 0.49 | 30.0 (7.3) | 30.1 (7.5) | 0.68 |
Insuranceb
| ||||||
Medicare, n (%) | 321 (32.9) | 1363 (26.0) | < 0.001 | 315 (33.1) | 293 (30.8) | 0.28 |
Medicaid, n (%) | 48 (4.9) | 327 (6.2) | 0.12 | 48 (5.0) | 59 (6.2) | 0.32 |
Private, n (%) | 712 (73.0) | 4034 (77.0) | 0.01 | 700 (73.5) | 719 (75.5) | 0.32 |
None, n (%) | 23 (2.4) | 136 (2.6) | 0.74 | 22 (2.3) | 14 (1.5) | 0.24 |
Clinical characteristics | ||||||
Age at RA onset, years, mean (SD) | 46.9 (14.4) | 47.4 (13.5) | 0.35 | 47.0 (14.4) | 46.7 (13.8) | 0.73 |
Disease duration, years, median (IQR) | 9 (12.0) | 5 (10.0) | < 0.001 | 9 (12.0) | 8 (12.5) | 0.26 |
CDAI, median (IQR) | 19.0 (20.2) | 17.0 (19.0) | 0.01 | 19.0 (20.2) | 18.5 (20.0) | > 0.99 |
mHAQ, median (IQR) | 0.5 (0.8) | 0.4 (0.8) | < 0.001 | 0.5 (0.8) | 0.5 (0.8) | 0.89 |
History of comorbidities | ||||||
Diabetes, n (%) | 75 (7.7) | 467 (8.9) | 0.22 | 75 (7.9) | 96 (10.1) | 0.09 |
Pulmonary disease,c n (%) | 58 (5.9) | 347 (6.6) | 0.43 | 58 (6.1) | 64 (6.7) | 0.57 |
Cardiovascular disease,d n (%) | 57 (5.8) | 283 (5.4) | 0.57 | 54 (5.7) | 57 (6.0) | 0.77 |
Malignancy,e n (%) | 48 (4.9) | 225 (4.3) | 0.38 | 46 (4.8) | 45 (4.7) | 0.91 |
Serious infection,f n (%) | 64 (6.6) | 348 (6.6) | 0.93 | 63 (6.6) | 80 (8.4) | 0.14 |
Comorbidity indexg
| ||||||
Median score (IQR) | 1 (0) | 1 (0) | 0.60 | 1 (0) | 1 (0) | 0.12 |
Score ≥ 2, n (%) | 197 (21.1) | 1029 (20.3) | 0.60 | 191 (20.9) | 216 (23.7) | 0.16 |
Line of TNFi therapy | < 0.001h
| 0.69h
| ||||
First, n (%) | 253 (25.9) | 2594 (49.5) | 250 (26.3) | 236 (24.8) | ||
Second, n (%) | 285 (29.2) | 1593 (30.4) | 276 (29.0) | 290 (30.5) | ||
Third or later, n (%) | 437 (44.8) | 1053 (20.1) | 426 (44.7) | 426 (44.7) | ||
Concomitant DMARD use | ||||||
Nonbiologic DMARDs (excluding MTX), n (%) | 146 (15.0) | 819 (15.6) | 0.60 | 143 (15.0) | 166 (17.4) | 0.15 |
MTX and other nonbiologic DMARDs, n (%) | 85 (8.7) | 661 (12.6) | < 0.001 | 84 (8.8) | 105 (11.0) | 0.11 |
MTX (excluding other nonbiologic DMARDs), n (%) | 469 (48.0) | 2597 (49.6) | 0.40 | 456 (47.9) | 450 (47.3) | 0.78 |
Concomitant prednisone use | 0.45h
| 0.26h
| ||||
None, n (%) | 679 (70.1) | 3695 (70.9) | 661 (69.9) | 658 (69.3) | ||
< 10 mg/day, n (%) | 197 (20.4) | 982 (18.8) | 193 (20.4) | 179 (18.9) | ||
≥ 10 mg/day, n (%) | 92 (9.5) | 538 (10.3) | 91 (9.6) | 112 (11.8) |
Observed incidence of AEs in the unmatched population
CZP (n = 975) | Other TNFi (n = 5240) | |||||
---|---|---|---|---|---|---|
PY at riska
| Eventsb
| IR/100 PY (95% CI) | PY at riska
| Eventsb
| IR/100 PY (95% CI) | |
Serious infectious events
| 820 | 59 |
7.20 (5.58, 9.29)
| 4566 | 215 |
4.71 (4.12, 5.38)
|
Joint/bursa | 847 | 2 | 0.24 (0.06, 0.94) | 4660 | 16 | 0.34 (0.21, 0.56) |
Cellulitis/skin | 841 | 13 | 1.55 (0.90, 2.66) | 4650 | 36 | 0.77 (0.56, 1.07) |
Sinusitis | 847 | 2 | 0.24 (0.06, 0.94) | 4660 | 10 | 0.21 (0.12, 0.40) |
Diverticulitis | 847 | 2 | 0.24 (0.06, 0.94) | 4660 | 10 | 0.21 (0.12, 0.40) |
Sepsis | 848 | 1 | 0.12 (0.02, 0.84) | 4657 | 16 | 0.34 (0.21, 0.56) |
Pneumonia | 842 | 15 | 1.78 (1.07, 2.95) | 4641 | 58 | 1.25 (0.97, 1.62) |
Bronchitis | 846 | 5 | 0.59 (0.25, 1.42) | 4660 | 11 | 0.24 (0.13, 0.43) |
Gastroenteritis | 847 | 4 | 0.47 (0.18, 1.26) | 4659 | 14 | 0.30 (0.18. 0.51) |
Meningitis/encephalitis | 848 | 0 | 0 (NC) | 4665 | 2 | 0.04 (0.01, 0.17) |
Urinary tract infection | 842 | 10 | 1.19 (0.64, 2.21) | 4650 | 29 | 0.62 (0.43, 0.90) |
Upper respiratory infection | 848 | 2 | 0.24 (0.06, 0.94) | 4660 | 10 | 0.21 (0.12, 0.40) |
Active tuberculosisc
| 848 | 0 | 0 (NC) | 4664 | 2 | 0.04 (0.01, 0.17) |
Other | 844 | 9 | 1.07 (0.55, 2.05) | 4649 | 36 | 0.77 (0.56, 1.07) |
Identified serious infectious organism
| 839 | 15 |
1.79 (1.08, 2.96)
| 4636 | 65 |
1.40 (1.10, 1.79)
|
Opportunistic | 848 | 0 | 0.00 (NC) | 4664 | 2 | 0.04 (0.01, 0.17) |
Nonopportunistic | 843 | 8 | 0.95 (0.47, 1.90) | 4648 | 30 | 0.65 (0.45, 0.92) |
Unknown | 844 | 7 | 0.83 (0.40, 1.74) | 4648 | 34 | 0.73 (0.52, 1.02) |
Malignancies
| 841 | 15 |
1.78 (1.08, 2.96)
| 4622 | 96 |
2.08 (1.70, 2.54)
|
Lymphoma | 848 | 0 | 0 (NC) | 4664 | 4 | 0.09 (0.03, 0.23) |
Breast cancer | 848 | 1 | 0.12 (0.02, 0.84) | 4660 | 9 | 0.19 (0.10, 0.37) |
Lung cancer | 848 | 2 | 0.24 (0.06, 0.94) | 4664 | 3 | 0.06 (0.02, 0.20) |
Skin cancer – melanoma | 848 | 0 | 0 (NC) | 4662 | 6 | 0.13 (0.06, 0.29) |
Skin cancer – basal/squamous | 845 | 5 | 0.59 (0.25, 1.42) | 4641 | 49 | 1.06 (0.80, 1.40) |
Other cancer | 844 | 7 | 0.83 (0.40, 1.74) | 4655 | 26 | 0.56 (0.38, 0.82) |
Cardiovascular events
| 840 | 17 |
2.02 (1.26, 3.26)
| 4633 | 77 |
1.66 (1.33, 2.08)
|
Myocardial infarction | 847 | 3 | 0.35 (0.11, 1.10) | 4661 | 11 | 0.24 (0.13, 0.43) |
TIA/stroke | 846 | 5 | 0.59 (0.25, 1.42) | 4650 | 34 | 0.73 (0.52, 1.02) |
Other cardiovascular eventd
| 843 | 10 | 1.19 (0.64, 2.20) | 4649 | 43 | 0.93 (0.69, 1.25) |
Other AEs of interest
| ||||||
Anaphylaxis/allergic reaction | 845 | 4 | 0.47 (0.18, 1.26) | 4660 | 14 | 0.30 (0.18, 0.51) |
Drug-induced SLE | 848 | 0 | 0 (NC) | 4665 | 0 | 0 (NC) |
Gastrointestinal perforation | 848 | 0 | 0 (NC) | 4663 | 3 | 0.06 (0.02, 0.20) |
Hepatic event | 848 | 0 | 0 (NC) | 4660 | 10 | 0.21 (0.12, 0.40) |
Progressive multifocal leukoencephalopathy | 848 | 0 | 0 (NC) | 4665 | 0 | 0 (NC) |
Other neurological event (with hospitalization)/other demyelinating disease | 848 | 0 | 0 (NC) | 4664 | 4 | 0.09 (0.03, 0.23) |
Spontaneous serious bleeding | 848 | 0 | 0 (NC) | 4664 | 5 | 0.11 (0.04, 0.26) |
Observed incidence of AEs in the PS-matched population
CZP (n = 952) | Other TNFi (n = 952) | |||||
---|---|---|---|---|---|---|
PY at riska
| Eventsb
| IR/100 PY (95% CI) | PY at riska
| Eventsb
| IR/100 PY (95% CI) | |
Serious infectious events
| 799 | 57 |
7.13 (5.50, 9.25)
| 814 | 46 |
5.65 (4.23, 7.54)
|
Joint/bursa | 825 | 2 | 0.24 (0.06, 0.97) | 836 | 3 | 0.36 (0.12, 1.11) |
Cellulitis/skin | 820 | 13 | 1.59 (0.92, 2.73) | 833 | 9 | 1.08 (0.56, 2.08) |
Sinusitis | 826 | 2 | 0.24 (0.06, 0.97) | 835 | 2 | 0.24 (0.06, 0.96) |
Diverticulitis | 826 | 2 | 0.24 (0.06, 0.97) | 835 | 2 | 0.24 (0.06, 0.96) |
Sepsis | 826 | 1 | 0.12 (0.02, 0.86) | 836 | 3 | 0.36 (0.12, 1.11) |
Pneumonia | 821 | 15 | 1.83 (1.10, 3.03) | 833 | 9 | 1.08 (0.56, 2.08) |
Bronchitis | 825 | 5 | 0.61 (0.25, 1.46) | 835 | 2 | 0.24 (0.06, 0.96) |
Gastroenteritis | 825 | 4 | 0.48 (0.18, 1.29) | 834 | 5 | 0.60 (0.25, 1.44) |
Meningitis/encephalitis | 827 | 0 | 0 (NC) | 837 | 1 | 0.12 (0.02, 0.85) |
Urinary tract infection | 821 | 10 | 1.22 (0.66, 2.26) | 834 | 6 | 0.72 (0.32, 1.60) |
Upper respiratory infection | 827 | 2 | 0.24 (0.06, 0.97) | 835 | 3 | 0.36 (0.12, 1.11) |
Active tuberculosisc
| 827 | 0 | 0 (NC) | 837 | 1 | 0.12 (0.02, 0.85) |
Other | 823 | 7 | 0.85 (0.41, 1.78) | 832 | 9 | 1.08 (0.56, 2.08) |
Identified serious infection organism
| 819 | 14 |
1.71 (1.01, 2.89)
| 831 | 14 |
1.69 (1.00, 2.85)
|
Opportunistic | 827 | 0 | 0 (NC) | 836 | 2 | 0.24 (0.06, 0.96) |
Nonopportunistic | 822 | 8 | 0.97 (0.49, 1.95) | 835 | 4 | 0.48 (0.18, 1.28) |
Unknown | 824 | 6 | 0.73 (0.33, 1.62) | 834 | 8 | 0.96 (0.48, 1.92) |
Malignancies
| 821 | 14 |
1.71 (1.01, 2.88)
| 827 | 20 |
2.42 (1.56, 3.75)
|
Lymphoma | 827 | 0 | 0 (NC) | 836 | 2 | 0.24 (0.06, 0.96) |
Breast cancer | 827 | 1 | 0.12 (0.02, 0.86) | 837 | 0 | 0 (NC) |
Lung cancer | 827 | 2 | 0.24 (0.06, 0.97) | 837 | 0 | 0 (NC) |
Skin cancer – melanoma | 827 | 0 | 0 (NC) | 836 | 2 | 0.24 (0.06, 0.96) |
Skin cancer – basal/squamous | 825 | 4 | 0.48 (0.18, 1.29) | 833 | 8 | 0.96 (0.48, 1.92) |
Other cancer | 823 | 7 | 0.85 (0.41, 1.78) | 833 | 8 | 0.96 (0.48, 1.92) |
Cardiovascular events
| 819 | 17 |
2.08 (1.29, 3.34)
| 829 | 17 |
2.05 (1.27, 3.30)
|
Myocardial infarction | 825 | 3 | 0.36 (0.12, 1.13) | 837 | 1 | 0.12 (0.02, 0.85) |
TIA/stroke | 824 | 5 | 0.61 (0.25, 1.46) | 832 | 10 | 1.20 (0.65, 2.23) |
Other cardiovascular eventd
| 822 | 10 | 1.22 (0.65, 2.26) | 833 | 9 | 1.08 (0.56, 2.08) |
Other AEs of interest
| ||||||
Anaphylaxis/allergic reaction | 824 | 4 | 0.49 (0.18, 1.29) | 835 | 5 | 0.60 (0.25, 1.44) |
Drug-induced SLE | 827 | 0 | 0 (NC) | 837 | 0 | 0 (NC) |
Gastrointestinal perforation | 827 | 0 | 0 (NC) | 837 | 1 | 0.12 (0.02, 0.85) |
Hepatic event | 827 | 0 | 0 (NC) | 834 | 4 | 0.48 (0.18, 1.28) |
Progressive multifocal leukoencephalopathy | 827 | 0 | 0 (NC) | 837 | 0 | 0 (NC) |
Other neurological event (with hospitalization)/other demyelinating disease | 827 | 0 | 0 (NC) | 837 | 0 | 0 (NC) |
Spontaneous serious bleeding | 827 | 0 | 0 (NC) | 837 | 1 | 0.12 (0.02, 0.85) |